Cellular effects of a new farnesyltransferase inhibitor, RPR-115135, in a human isogenic colon cancer cell line model system HCT-116

Annals of the New York Academy of Sciences

Volumn 886, Issue , 1999, Pages 252-256

  Russo, P ^a,d   Ottoboni, C ^a,d   Falugi, C ^b   Reinhold, W ^a   Riou, J F ^c   Parodi, S ^c   O'Connor, P M ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c SANOFI   (France)

^d UNIVERSITY OF GENOA   (Italy)

^e AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RPR 115135; UNCLASSIFIED DRUG;

ANEUPLOIDY; CANCER CELL CULTURE; CANCER GROWTH; CELL STRUCTURE; COLON CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MICRONUCLEUS;

EID: 0033404078     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09429.x     Document Type: Conference Paper

References (15)

1. 1. Koo, H.-M. et al. 1996. Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogens. Cancer Res. 56: 5211-5216.
2. 2. Fan, S. et al. 1997, Cell lacking CIP1/WAF1 genes exhibits preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 14: 2127-2136.
3. 3. Gibbs, J.B & A. Oliff, 1997. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Ann. Rev. Pharmacol. Toxicol. 37: 143-166.
4. 4. Leonard, D.M. 1997. Ras farnesyltransferase. A new therapeutic target. Med. Chem. 40: 2971-2990.
5. 5. Lerner, E.C. et al. 1997. Inhibition of Ras prenylation: A signaling target for novel anti-cancer drug design. Anti-Cancer Drug Design 12: 229-238.
6. 6. Maillet, P. et al. 1997. Synthesis and in vitro structure-activity relationship of a new promising series of non peptidic protein-farnesyl-transferase inhibitors. Proc. Am. Assoc. Cancer Res. 8: 350.
7. 7. Omerch, A. et al. 1997. Farnesylproteintransferase inhibitors as agents to inhibit tumor growth. BioFactors 6: 359-366.
8. 8. Qian, Y. et al. 1997. Farnesyltransferase as a target for anticancer drug design. Biopolymer 43: 25-41.
9. 9. Sebti, S.M. & A.D. Hamilton. 1997. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol. Ther. 74: 103-114.
10. 10. Katz, M.E. & F. McCormick. 1997. Signal transduction from multiple Ras effectors. Curr. Opin. Gen. Dev. 7: 75-79.
11. 11. Khosravi-Far, R. et al. 1996. Oncogenic Ras activation of Raf/mitogen-activated protein kinase independent pathways is sufficient to cause tumorigenic transformation. Mol. Cell. Biol. 16: 3923-3933.
12. 12. Zachos, G. & D.A. Spandidos. 1997. Expression of ras proto-oncogenes: Regulation and implications in the development of human tumors. Crit. Rev. Oncol. Hematol. 26: 65-75.
13. 13. White, A.M. et al. 1995. Multiple Ras functions can contribute to mammalian cell transformation. Cell 80: 533-541.
14. 14. Clerc, F.F. et al. 1995. Constrained analogs of KCVFM with improved inhibitory properties against farnesyl transferase. Bioorg. Med. Chem. Lett. 5: 1779-1784.
15. 15. Genetic Toxicology and Environmental Mutagenesis. Special Issue: 1997. The CB in vitro micronucleus assay in human lymphocytes. Mut. Res. 392: 1-280.